abstract |
The present invention relates to a method of diagnosing or prognosing metastasis in prostate cancer, comprising the step of ascertaining whether the c-MAF gene is amplified in a primary tumor sample. The present invention also relates to a method of measuring the tendency to cause bone metastasis relative to metastasis in other organs, including a method of diagnosing or prognosing metastasis in prostate cancer, as well as measuring c-MAF expression level . Finally, the present invention relates to the use of a c-MAF inhibitor as a therapeutic target for treating prostate cancer. |